DUBLIN, Ireland–(EMWNews)–Research and Markets (http://www.researchandmarkets.com/research/ab3a2c/france_pharmaceuti)

has announced the addition of the “France Pharmaceuticals and Healthcare

Report Q2 2008” report to their offering.

The France Pharmaceuticals and Healthcare Report provides independent

forecasts and competitive intelligence on Frances pharmaceuticals and

healthcare industry.

The French pharmaceutical sector is both large and dynamic with

traditional strengths in production, and research & development (R&D).

However, the government has decided that it can no longer support the

conventionally generous state-spending on medicine, and has demanded

that austerities be made in the sector. This appears to have had an

impact in the last couple of years. But in 2007, growth crept up again

by 3.5%, bringing the total market value to US$32.4bn. A part of the

problem was that reimbursed drug spending for salaried workers had

picked up and doctors were accused of not implementing prescribing

restrictions correctly.

Meanwhile, President Nicolas Sarkozy has continued with his promises of

the past with a number of initiatives for the health sector. Besides

stripping early retirees of their right to free healthcare, Sarkozy has

launched a five-year plan to tackle Alzheimers disease, which will be

funded by the recent imposition of a surcharge on medicine packs. The

EUR1.6bn (US$2.4bn) plan will create a new research foundation to pool

scientific resources and will set up a series of nursing homes. The

surcharge programme, which was launched in January 2008, is raising

revenues at the forecast level and is not resulting in falling demands

for medicines.

On the other hand, France’s government healthcare advisory body, La

Haute Autorité de Santé

(HAS), has concluded that the country should reform the way chronic

diseases are treated. BMI believes that the authorities will be keen to

act on some of HAS’s suggestions to reduce the

social security budget deficit. But any attempts perceived to involve a

rationing of care will likely be met with fierce opposition, from both

consumer groups and industry stakeholders. France has maintained its

third position in BMI’s Business Environment

Rankings for the Western European region. However, the French

pharmaceutical association LEEM, has called for the government to

provide greater support in R&D within the pharmaceutical sector.

Specifically, the industry wants to see closer ties forged between

public research and private enterprise.

Key Topics Covered:

Executive Summary

France Pharmaceuticals And Healthcare Industry SWOT

France Political SWOT

France Economic SWOT

Pharmaceutical Business Environment Ratings

Risks To Realisation Of Returns

Table: Western Europe Pharmaceutical Business Environment Rankings

France – Market Summary

Regulatory Regime

Intellectual Property Developments

Pricing And Reimbursement Issues

FRANCE REIMBURSEMENT CATEGORIES

Industry Developments

Healthcare Sector

Public Health Issues

Domestic Industry

Table: Major Mergers And Acquisitions, 2006 (US$)

Foreign Companies

Product Approvals

Research And Development Sector

Biotechnology Sector

Table: New French Taxes On Private-Sector Research Applications

Parallel Trade

Table: First Parallel Imports In France

Clinical Research

Pharmacy Sector

Epidemiology

Wholesale Sector

Generics Sector

Industry Forecast Scenario

Overall Market Forecast

Table: France Drug Market Expenditure Forecast Indicators

Key Factors – Industry

Table: France’s Health Expenditure Indicators,

2005-2012

Key Growth Factors – Macroeconomic

Table: France – Macroeconomic Forecasts

Patented Market Forecast

Table: France Patented Drugs Market Forecast Indicators (US$mn unless

otherwise stated)

OTC Market Forecast

Table: France OTC Drugs Market Forecast Indicators (US$mn unless

otherwise stated)

Generics Market Forecasts

Table: France’s Generics And Branded Drugs

Market Indicators

Export/Import Forecasts

Table: Sectoral Trade Indicators (US$mn)

Other Healthcare Data And Forecasts

Table: Socio-Demographic Indicators

Key Risks To BMI’s Forecasts

Company Profiles

Leading Multinational Manufacturers

– Sanofi-Aventis

– Pfizer

– GlaxoSmithKline (GSK)

– Novartis

– Merck & Co

Major Indigenous Companies

– Servier

– Ipsen

Our Forecast Modelling

How We Generate Our Industry Forecasts

Pharmaceutical Industry

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources

For more information visit http://www.researchandmarkets.com/research/ab3a2c/france_pharmaceuti

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions